484 related articles for article (PubMed ID: 22555507)
1. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
[TBL] [Abstract][Full Text] [Related]
3. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
5. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
[TBL] [Abstract][Full Text] [Related]
6. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
Ahmed AU; Thaci B; Tobias AL; Auffinger B; Zhang L; Cheng Y; Kim CK; Yunis C; Han Y; Alexiades NG; Fan X; Aboody KS; Lesniak MS
J Natl Cancer Inst; 2013 Jul; 105(13):968-77. PubMed ID: 23821758
[TBL] [Abstract][Full Text] [Related]
7. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
[TBL] [Abstract][Full Text] [Related]
8. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.
Sonabend AM; Ulasov IV; Han Y; Rolle CE; Nandi S; Cao D; Tyler MA; Lesniak MS
Cancer Gene Ther; 2009 Apr; 16(4):362-72. PubMed ID: 19011597
[TBL] [Abstract][Full Text] [Related]
10. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
11. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
Kim JW; Auffinger B; Spencer DA; Miska J; Chang AL; Kane JR; Young JS; Kanojia D; Qiao J; Mann JF; Zhang L; Wu M; Ahmed AU; Aboody KS; Strong TV; Hébert CD; Lesniak MS
J Transl Med; 2016 May; 14(1):134. PubMed ID: 27184224
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
13. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
Morshed RA; Gutova M; Juliano J; Barish ME; Hawkins-Daarud A; Oganesyan D; Vazgen K; Yang T; Annala A; Ahmed AU; Aboody KS; Swanson KR; Moats RA; Lesniak MS
Cancer Gene Ther; 2015 Jan; 22(1):55-61. PubMed ID: 25525033
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
[TBL] [Abstract][Full Text] [Related]
15. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
16. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.
Ulasov IV; Tyler MA; Rivera AA; Nettlebeck DM; Douglas JT; Lesniak MS
J Med Virol; 2008 Sep; 80(9):1595-603. PubMed ID: 18649343
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
[TBL] [Abstract][Full Text] [Related]
19. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
[TBL] [Abstract][Full Text] [Related]
20. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]